menu search

APLS / Apellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Adam Townsend - Chief Commercial Officer Cedric Francois - Co-Founder, President & Chief Executive Officer Federico Grossi - Co-Founder & Chief Medical Officer Meredith Kaya - Senior Vice President, Investor Relations & Strategic Finance Timothy Sullivan - Chief Financial Officer Conference Call Participants Tazeen Ahmad - BAML Jon Miller - Evercore Anupam Rama - JPMorgan Philip Nadeau - Cowen Steven Seedhouse - Raymond James Chris Howerton - Jefferies Colleen Kusy - Baird Justin Kim - Oppenheimer Yigal Nochomovitz - Citi Ellie Merle - UBS Annabel Samimy - Stifel Douglas Tsao - H.C. Wainwright Operator Hello, and thank you for standing by. Read More
Posted: Nov 8 2022, 01:26
Author Name: Seeking Alpha
Views: 110683

APLS News  

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

By Zacks Investment Research
November 2, 2023

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in t more_horizontal

Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Fo more_horizontal

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
November 1, 2023

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This co more_horizontal

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

By GlobeNewsWire
October 25, 2023

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conferen more_horizontal

New Strong Buy Stocks for October 24th

By Zacks Investment Research
October 24, 2023

New Strong Buy Stocks for October 24th

MFA, GFF, OPI, APLS and GRPN have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2023. more_horizontal

Pharma Stock Upgraded on Eye Disorder Drug Sales

By Schaeffers Research
October 6, 2023

Pharma Stock Upgraded on Eye Disorder Drug Sales

Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P. more_horizontal

Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:

By Yahoo Finance
October 6, 2023

Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:

Stocks take in the morning's September jobs report data. e.l.f. Beauty (ELF) shares tick up this morning following an upgrade to "Buy" from Jefferies more_horizontal

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

By The Motley Fool
September 27, 2023

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

Apellis just got a J-code for reimbursement for its lead therapy from CMS. The company saw revenue climb 473% year over year in the second quarter. more_horizontal


Search within

Pages Search Results: